Your browser doesn't support javascript.
loading
Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial.
Gui, Yu-Zhou; Li, Xue-Ning; Li, Jing-Xin; Shen, Ming-Yun; Zhang, Mei-Wei; Cao, Ye; Xu, Hong-Rong; Li, Hui; Cheng, Jie; Pan, Liang; Yi, Ying-Lei; Liang, Li-Yu; Yu, Cheng-Yin; Liu, Gang-Yi; Yu, Chen; Hu, Bi-Jie; Zhu, Feng-Cai; Liang, Fei; Shen, Haifa; Jia, Jing-Ying; Li, Hang-Wen; Zhou, Jian; Fan, Jia.
Afiliação
  • Gui YZ; Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Li XN; Zhongshan Hospital, Fudan University, Shanghai, China.
  • Li JX; Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
  • Shen MY; StemiRNA Therapeutics Co., Ltd., Shanghai, China.
  • Zhang MW; Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Cao Y; Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Xu HR; Zhongshan Hospital, Fudan University, Shanghai, China.
  • Li H; Zhongshan Hospital, Fudan University, Shanghai, China.
  • Cheng J; Zhongshan Hospital, Fudan University, Shanghai, China.
  • Pan L; Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Yi YL; StemiRNA Therapeutics Co., Ltd., Shanghai, China.
  • Liang LY; Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Yu CY; Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Liu GY; Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Yu C; Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Hu BJ; Zhongshan Hospital, Fudan University, Shanghai, China.
  • Zhu FC; Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
  • Liang F; Zhongshan Hospital, Fudan University, Shanghai, China.
  • Shen H; StemiRNA Therapeutics Co., Ltd., Shanghai, China.
  • Jia JY; Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Li HW; StemiRNA Therapeutics Co., Ltd., Shanghai, China.
  • Zhou J; Zhongshan Hospital, Fudan University, Shanghai, China.
  • Fan J; Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: fan.jia@zs-hospital.sh.cn.
EBioMedicine ; 91: 104586, 2023 May.
Article em En | MEDLINE | ID: mdl-37099843
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article